Recursion Pharmaceuticals

01/22/2026

Our TechBio Talks Live event at offered real insights about the state of AI drug discovery and the broader healthcare ecosystem.

Award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up to Cancer, Katie Couric led the discussions – including a fireside chat with Recursion CEO and President Najat Khan and a panel discussion with some of the people leading what Najat called “this new era of AI translation.” As she said: “It’s no longer, can we do this? It’s around what value does this actually create? And how does this show up in the lives of patients that are waiting?”

💡 Insights included:

▪️ From Renee Gala, President and CEO of Jazz Pharmaceuticals: “When you think about patient identification, there are so many advances now coming through AI that allow us to better identify patients, better identify what the biomarkers are.”

▪️ From Reid Hoffman, Co-founder, LinkedIn, Manas AI, & Inflection AI: “The idea when you have a target is not to spend 10 years seeing if it works,” but “how do you have AI help you actually force rank targets vis-a-vis feasibility, give you lots of variation of answers that you then cycle on very quickly?”

▪️ From Eric Lefkofsky, Founder & CEO, Tempus AI: “We’ve just built this giant self-learning machine that collects longitudinal clinical data, on about half the United States population who have cancer” and are “sequencing as many patients as we can...to figure out over time how to move from really targeted therapeutics to precision medicine.”

▪️ From Eric Topol, Chair, Department of Translational Medicine, Scripps Research: Although “Physicians are squeezed” and “clinicians are heading towards burnout and disenchantment,” AI is leading to a real flip – “And that’s what’s so exciting right now. Because we’re seeing for the first time, this is where AI, the near term, is really kicking in.”

Look for full versions of the talks on our YouTube channel: https://www.youtube.com/

TechBio

01/20/2026

At JPM, Recursion CEO and President Najat Khan, PhD spoke with Brad Loncar of BiotechTV about her vision for the company, Recursion’s competitive advantages, and the pipeline programs providing the clinical proof points for our platform’s novel insights.

🔹 Some highlights:

▪️ How do you want people to think about Recursion going forward?

“Fundamentally, Recursion is here to build differentiated medicines at scale for patients who are waiting. How we do it is different. We are the only AI native company that is end-to-end, leveraging AI across discovering novel biology, designing small molecules, and accelerating clinical development.”

▪️ You mentioned in your company presentation that your MEK inhibitor was the first example of finding something with the platform that surprised you. Tell us what that is.

“We found that this allosteric MEK 1/2 inhibitor actually reversed the disease to a healthy state in cellular models of FAP on our platform. That was that first biological insight. There was no connection back then that MEK inhibition could lead to rescuing APC loss of function. We then did all of the great in vivo work. We licensed that asset from a pharma company that had shelved it after studying it in solid tumors. And now we’re seeing the clinical data and what we see is rapid and durable polyp burden reduction – higher than what others have seen to date.”

👉 Watch the full interview: https://www.biotechtv.com/post/recursion-january-14-2026

01/16/2026

We were honored to host a packed TechBio Talks Live event at the San Francisco Mint at JPM with an introduction from CEO and President Najat Khan and a fireside chat with Najat and award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up to Cancer, Katie Couric.

Katie moderated a panel discussion on the future of AI in healthcare and medicine featuring:
▪️ Renee Gala, President and CEO of Jazz Pharmaceuticals
▪️ Reid Hoffman, Co-founder, LinkedIn, Manas AI, & Inflection AI
▪️ Eric Lefkofsky, Founder & CEO, Tempus
▪️ Eric Topol, Chair, Department of Translational Medicine, Scripps Research
They discussed the best places to deploy capital to drive AI innovation in healthcare; how to distinguish clinical impact from AI hype; and how technology is positioned to impact patients.

Thank you to all the panelists and guests who attended – we’ll be sharing more highlights and videos from this incredible night in the weeks to come!

01/14/2026

🎙️ Bringing TechBio Talks Live to .

Last year, we launched a new podcast – TechBio Talks – to explore the bold ideas, breakthrough technologies, and visionary people reshaping AI and medicine. Tonight, we’re bringing together some of the biggest names at the intersection of tech, AI, and healthcare for the first live edition of TechBio Talks for our annual event at the J.P. Morgan Healthcare Conference.

….Stay tuned for more! ⏲️

01/13/2026

The era of AI proof points: from novel insights to clinically meaningful outcomes for patients.

In a company presentation at the jp Morgan Healthcare Conference, Recursion CEO and President Najat Khan, PhD noted that we’ve shifted from a focus on whether AI can work to the era of ex*****on and delivering clinical impact.

Recursion is the only company with a “truly unified AI-native intelligence platform,” Najat said, one that seamlessly connects from idea through the clinic – systems-level biology with precision chemical design directly tied to patient data.

Now, Recursion is taking its three major competitive advantages – proprietary data, state-of-the-art models and compute, and bilingual people and culture bridging science and technology – to accelerate this outcomes-focused era.

She noted that, in December, Recursion demonstrated the first clinical proof of concept of the Recursion OS with the REC-4881 program for FAP – a disease with no approved medicines.

🔹 Looking ahead, Najat said she’s focused on three key pillars:

▪️ Pillar 1: Evidence of meaningful clinical outcomes: across pipeline and partnerships, we’re looking for unequivocal evidence that novel insights from our platform can translate into meaningful clinical outcomes in the form of differentiated medicines, as with the FAP data.

▪️ Pillar 2: Innovation grounded in clear impact: being judicious and laser-focused with our investments, building in areas where we can have the highest impact on making medicines and where we have a competitive advantage.

▪️ Pillar 3: Pairing bold ambition with discipline: advancing bold goals, which we can achieve through disciplined capital allocation and flawless ex*****on.

“The foundation is our people,” Najat added, “industry-leading, bilingual talent and culture all driven by our mission.”

👉 See the full JPM webcast here: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317363-recursion-pharma-inc/webcast/general_signin?gpu_only=true&kiosk=true

01/09/2026

Leveraging AI and real-world patient data to accelerate drug discovery and build a new paradigm for precision medicine.

In a recent webinar with our partners, , Sid Jain, SVP of Clinical Development and Data Science at Recursion and hayley, VP of Frontier Research, spoke to Shane Woods, Chief Strategy Officer at Tempus about how patient data is driving the latest advances in AI drug discovery.

🔹 Highlights:

▪️ How combining Tempus’ real-world patient data with Recursion’s experimental data is unlocking new programs.

Hayley: “The patient data tells you what genes are associated with a disease, and our perturbational data tells you why. Layering these two views into our causal AI models allows us to finally move from correlation to causation. This helps us amplify signals that would normally require hundreds of thousands of patient samples to detect, which is a massive unlock for rare diseases and small patient cohorts.”

▪️ How this integrated TechBio approach helps to de-risk key clinical development decisions.

Sid: “We have used these integrated datasets to reprioritize indications for in-development assets, giving us more confidence in where to proceed and, just as importantly, where to stop. This is critical from both a probability of success and an ethical perspective. If we can better predict who will or will not respond, we can target trials to patients most likely to benefit. We have also used the data to refine inclusion and exclusion criteria in our protocols.”

👉 Read more insights from the webinar here: https://www.tempus.com/resources/content/articles/qa-how-techbio-and-multimodal-data-are-reshaping-rd/

01/08/2026

📅 New year.

📽️ New 101 video.

🚀 Same relentless ambition.

➡️ See you at !

https://youtu.be/NzerLX6koWI?si=cRz0uzX8rT2HHgJd

01/05/2026

At Recursion, we get to do some pretty incredible work at the cutting edge of science and technology.

In this video, Communications & Culture Fellow Katherine Matsumoto asks the question: what is one thing that 8-year-old you would be excited that you get to do every day? (Spoiler alert: Making discoveries with computers and working with robots are both high on the list!)

12/18/2025

🎉 Recursion’s Chief Platform Officer Lina Nilsson was recently chosen for the AI Women Power List by AI Utah and the Women Tech Council. 🎉

The award recognizes women who have demonstrated leadership in advancing AI and are setting an example for innovators across the state.

Lina joined Recursion in 2018 and became the company’s first Chief Platform Officer in May 2025.

She has championed an AI-first approach to end-to-end drug discovery and ensures that we are pushing the boundaries of what the Recursion OS can do with continued investment in AI, ML, and automation, and in translating those advances into real impact for patients.

🙌 Congrats to Lina on this well-deserved recognition!

12/17/2025

🔹 AI drug discovery, validated.

Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP).

This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery.

Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population.

It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives.

👉 See the full study results here: https://ir.recursion.com/news-releases/news-release-details/positive-phase-1b2-results-ongoing-rec-4881-tupelo-trial-0

12/16/2025

How is real-world data transforming healthcare and medicine?

In the latest episode of our podcast, TechBio Talks, host Najat Khan, PhD, talks to Amy Abernethy, MD, PhD, cofounder of Highlander Health.

Amy is a physician, innovator, and executive who has pioneered oncology real-world evidence generation to address gaps in patient care and access.

They talk about the three “waves” of real-world data leading to today’s multimodal data; how that real-world data ties into patients’ longitudinal health story; and the difference between real-world data and real-world evidence. And they dive into how this data is driving major innovative shifts to improve clinical trials and drug discovery.

🎙️Listen and follow on:

➡️ Spotify: https://
open.spotify.com/episode/5alrWa
eoXJ0Sqni56UAPV1

➡️ YouTube: https://
youtube.com/watch?v=2JZoJR
LLZZk

➡️ Apple: https://
podcasts.apple.com/us/podcast/tec
hbio-talks-episode-4-highlander-healths-amy-abernethy/id1834770803?i=1000741516803

12/10/2025

Earlier this week, Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP). This data offers new hope for patients living with this relentlessly progressive disease, which currently has no approved pharmacotherapies.

As Beth shared, this data underscores the potential for REC-4881 to be a first-in-disease and best-in-class precision medicine to address the underlying biology of FAP.

👉 Watch Beth’s section of the webinar here: https://www.youtube.com/watch?v=mv0cOtYawqs

In this video, Beth Bruckheimer, PhD, VP of Clinical Development at Recursion, shared details on our positive Phase 1b/2 results from the ongoing TUPELO stud...